CellCyte Genetics Corp. is an emerging biotechnology company engaged in the discovery, development and commercialization of products that enhance the productivity of biotechnology research laboratories.
The company’s initial product line is comprised of the CCG-E45 culture chamber and related CCG-E45 incubator which have been in experimental use for the last several years. CellCyte announced today that it has signed a beta test collaboration agreement with the Fred Hutchinson Cancer Research Center in Seattle, Washington. The test is intended to evaluate the CCG-E45 culture chamber product as a supplement or replacement to their current methods of culturing specific cell lines.
CellCyte’s CCG-E45 culture chamber is a cell expansion device that allows the culture of cells at high density and under precisely controlled oxygenation. Shelly Heimfeld, PhD, director of the Cellular Therapy Laboratory and cGMP Cell Processing Facility at the Fred Hutchinson Cancer Research Center, will lead the team that will evaluate the use of the CCG-E45 culture chamber in their cord blood and T-cell culture systems.
Stock market reaction to the news has been very positive. The stock of CellCyte Genetics is currently trading at $0.0205, up $0.0064 or 45.39% for the day, on more than double the average daily volume. For further information about CellCyte Genetics, please visit its website at www.cellcyte.com.
Let us hear your thoughts below:
